drugset
drugset / Trial / NCT03764072

A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy

NCT03764072 ↗

Phase 2 Completed 250 enrolled Vertex Pharmaceuticals Incorporated
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the dose-response relationship and safety of VX-150 in treating acute pain following bunionectomy.

Timeline

Start
2018-12-12
Primary completion
2019-01-17
Completion
2019-01-25

Drugs

EvaluationDrugModalityDoseRoute
Subject VX-150 Unknown 250 mg Oral
Subject VX-150 Unknown 500 mg Oral
Subject VX-150 Unknown 750 mg Oral
Subject VX-150 Unknown 1000 mg Oral

Indications

No indication recorded.